BXYClinical Trials•globenewswire•
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Sentiment:Neutral (40)
Summary
Data from more than 2,600 agitation episodes collected
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 19, 2025 by globenewswire